Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Slides:

Advertisements

Similar presentations

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:

Advertisements

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) Adapted from Jones et al. SABCS 2008, abstract /477169/465253/454771/ /4146.

Weng TC, et al. J Clin Pharm Ther 2010;35:

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June.

Characteristics of Large Prospective Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. Alsheikh-Ali, et al. JACC 2007;50:

Shalev V, et al. Arch Intern Med 2009; 169:

Cholesterol Treatment Trialists’ (CTT) Collaboration. Lancet 2010;epub 9 Nov.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:

NICE –CG 181 Continuum of CVD Risk and its treatment

Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Copyright © 2011 American Medical Association. All rights reserved.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk. (A) Major vascular events, and (B) vascular.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Fig. 2. Comparative efficacy of thromboprophylaxis interventions in the prevention of deep vein thrombosis (DVT). (A) Estimated odds ratios (ORs) and 95%

Statin Myopathy (AHA/ACC/NHLBI)

Pravastatin in Elderly Individuals at Risk of Vascular Disease

A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.

Copyright © 2002 American Medical Association. All rights reserved.

APOC3 LOF heterozygotes have lower IVD and IHD risks due to lower RC

Copyright © 2012 American Medical Association. All rights reserved.

Oxford Niacin Trial.

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Neil J. Stone et al. JACC 2014;63:

A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.

A Systematic Review and Meta-Analysis

Jun M, et al. Lancet 2010 Epub May 10

Martin Bødtker Mortensen, and Erling Falk JACC 2018;71:85-94

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

APOC3, Coronary Disease, and Complexities of Mendelian Randomization

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis P.C. Minneci, K.J. Deans, P.Q. Eichacker, C. Natanson

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

David J.A. Jenkins et al. JACC 2018;71:

Classification of statins/dosages according to the attainable

Khurram Nasir et al. JACC 2015;66:

Potential mechanisms whereby statins may reduce the risk of stroke

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

Body mass, BMI, plasma lipids, lipoproteins, and glucose homeostasis at baseline, and following placebo and rosuvastatin periods Dmitri Sviridov et al.

Flow of Patients Through the Trial

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Baseline Characteristics of the Subjects*

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]

Disposition of Patients in the Atherogenic Dyslipidemia Study

Writing Committee Members et al. JACC 2018;j.jacc

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

Characteristics of included studies

Stavros V. Konstantinides et al. JACC 2017;69:

Change in markers of glycometabolism and cardiovascular risk profile.

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.

LDL-c reductions below 1

James H O'Keefe, Jr et al. JACC 2004;43:

Cryotherapy versus no cryotherapy for the reduction of severe oral mucositis in patients receiving treatment for cancer or undergoing haematopoietic stem.

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Medication intensity (ALLP) changes between baseline and 6 months, by (not) being low-density lipoprotein-cholesterol (LDL-C) target at baseline for nurse-coordinated.

Presentation transcript:

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Relationship Between On-Treatment LDL-C Levels and Incident Cancer in the Statin and Control Arms Each arm from each trial is considered an independent cohort of statin-treated or control individuals and is represented by an empty circle (with size proportional to each arm’s weight in the meta-regressions). Note how statin cohorts (arms) are shifted toward lower on-treatment low-density lipoprotein cholesterol (LDL-C) levels, while corresponding to the same range of incident cancer rates. Note the LDL-C scale on the horizontal axis. Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Risk of Cancer in Statin Versus Control Cohorts for Any Given Level of On-Treatment LDL-C Each trial is represented by an empty circle (with size proportional to its weight in the meta-regressions). The slope of the regression line represents the extent to which the incidence rate ratio for cancer depends on the on-treatment low-density lipoprotein cholesterol (LDL-C) level in the statin arms (p 0.73 for the effect of on-treatment LDL-C on the incidence rate ratio for cancer in statin vs. control cohorts). Note the LDL-C scale on the horizontal axis. Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Relationship Between On-Treatment LDL-C Levels and Incident Cancer Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]